TABLE 3.
Bacterial species (n) and drug | MIC (μg/ml)
|
% Susceptiblea | ||
---|---|---|---|---|
Range | 50% | 90% | ||
E. faecalis (3,491) | ||||
Vancomycin | 0.12–4 | 1 | 2 | 100 |
Teicoplanin | 0.03–1 | 0.12 | 0.12 | 100 (≤4) |
LY 333328 | 0.03–16 | 1 | 2 | 99 (≤4) |
Everninomicin | 0.015–2 | 0.25 | 1 | 100 (≤4) |
Quinupristin-dalfopristin | 0.03–64 | 4 | 8 | 25 (≤2) |
Erythromycin | 0.03–≥256 | 2 | ≥256 | 53 |
E. faecalis VRE (2) | ||||
Vancomycin | 256 | |||
Teicoplanin | 16–128 | |||
LY 333328 | 2 | |||
Everninomicin | 0.5–1 | |||
Quinupristin-dalfopristin | 4–8 | |||
Erythromycin | ≥256 | |||
E. faecium (552) | ||||
Vancomycin | 0.03–4 | 0.5 | 2 | 100 |
Teicoplanin | 0.03–1 | 0.25 | 0.25 | 100 |
LY 333328 | 0.03–2 | 0.5 | 1 | 100 |
Everninomicin | 0.015–2 | 0.5 | 1 | 100 |
Quinupristin-dalfopristin | 0.25–32 | 0.5 | 2 | 92 |
Erythromycin | 0.03–≥256 | 8 | ≥256 | 25 |
E. faecium VRE (22) | ||||
Vancomycin | 8–≥256 | ≥256 | ≥256 | 0 |
Teicoplanin | 0.12–256 | 32 | 128 | 27 |
LY 333328 | 0.12–2 | 1 | 2 | 100 |
Everninomicin | 0.12–1 | 0.5 | 1 | 100 |
Quinupristin-dalfopristin | 0.25–8 | 0.5 | 2 | 91 |
Erythromycin | 1–≥256 | ≥256 | ≥256 | 5 |
Other species (114) | ||||
Vancomycin | 0.25–4 | 0.5 | 4 | 100 |
Teicoplanin | 0.03–0.5 | 0.12 | 0.5 | 100 |
LY 333328 | 0.03–2 | 0.25 | 1 | 100 |
Everninomicin | 0.06–2 | 0.5 | 1 | 100 |
Quinupristin-dalfopristin | 0.06–8 | 1 | 4 | 87 |
Erythromycin | 0.03–≥256 | 2 | ≥256 | 51 |
Other species VRE (27) | ||||
Vancomycin | 8 | 8 | 8 | 0 |
Teicoplanin | 0.25–0.5 | 0.25 | 0.5 | 100 |
LY 333328 | 0.25–1 | 0.5 | 1 | 100 |
Everninomicin | 0.12–2 | 0.5 | 1 | 100 |
Quinupristin-dalfopristin | 1–4 | 2 | 2 | 96 |
Erythromycin | 0.03–≥256 | 1 | ≥256 | 81 |
Criteria are those published by the NCCLS. The MIC breakpoints chosen in case no criteria were given by the NCCLS were those of the class representatives (vancomycin for teicoplanin and LY333328; erythromycin for quinupristin-dalfopristin) or optional (everninomicin) and are given in parentheses.